Navigation Links
ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
Date:7/7/2008

The Association of American Medical Colleges (AAMC) recently approved guidelines "Industry Funding of Medical Education" not only addresses funding of medical education, but also provides guidelines to help medical schools and teaching hospitals better manage their relationships with industry. An important element of these guidelines is the clear separation of ghostwriting versus transparent writing collaboration in scientific publications. Unfortunately, the medical writer's role is poorly understood by many, but the International Society of Medical Publication Professionals (ISMPP) is working to clarify these misconceptions by defining the legitimate role of the medical writer while also supporting complete and transparent disclosure. ISMPP concurs with organizations like AAMC who increase recognition and understanding of the many issues involved in the collaborative process of medical writing and publication planning.

Ewing, NJ (PRWEB) July 7, 2008 -- The Association of American Medical Colleges (AAMC) recently approved guidelines, "Industry Funding of Medical Education" (www.aamc.org/industryfunding) not only addresses funding of medical education, but also provides guidelines to help medical schools and teaching hospitals better manage their relationships with industry. An important element of these guidelines is the clear separation of ghostwriting versus transparent writing collaboration in scientific publications.

"Unfortunately, the medical writer's role is poorly understood by many", said Gene Snyder, President of the International Society of Medical Publication Professionals (ISMPP). "ISMPP is working to clarify these misconceptions by defining the legitimate role of the medical writer while also supporting complete and transparent disclosure. We concur with organizations like AAMC who increase recognition and understanding of the many issues involved in the collaborative process of medical writing and publication planning".

AAMC has appropriately defined ghostwriting "as the provision of written material that is officially credited to someone other than the writer(s) of the material. Transparent writing collaboration with attribution between academic and industry investigators, medical writers, and/or technical experts is not ghostwriting. The unacknowledged, undisclosed provision of content should not be permitted under any circumstances". AAMC further provides the following recommendation: "Academic medical centers should prohibit physicians, trainees, and students from allowing their professional presentations of any kind, oral or written, to be ghostwritten by any party, industry or otherwise."

"Heightened awareness and rigorous examination of academic and industry involvement with clinical publications has become an increasingly prevalent topic in the medical literature. As is often the case with media scrutiny, attribution of poor practices in one area are generalized to a larger characterization of the issue at large, albeit unjustly in many cases", said Al Weigel, Chairman of ISMPP's Ethics Committee. "AAMC's guidelines provide a clear distinction between medical writing and ghostwriting/ghost authoring that is in line with the ISMPP Code of Ethics (http://www.ismpp.org), which is intended to promote quality clinical publication practices."

About ISMPP:
The International Society for Medical Publication Professionals is an independent nonprofit professional association with members from the pharmaceutical, medical device, and biotechnology industries; publication planning and medical communications companies; academia; and medical journal staff, including editors and publishers. Its goals are to support the education needs of publication professionals and to develop best practices that ensure the rigorous maintenance of all ethical standards for reporting the results of medical research. Additional information about ISMPP is available by contacting the organization's Executive Director, Kimberly Goldin (phone 914-945-0507, e-mail kgoldin@ismpp.org), or online at http://www.ismpp.org.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
2. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
3. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
4. FRC Applauds New Ballot Initiative for Cures Without Cloning
5. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
6. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. U-M research: New plastic is strong as steel, transparent
9. Facelift for Resumes Offers Hope for Job Seekers, says Resume Writing Service
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):